Clinical trial
Gefitinib in Treating Patients With Malignant Mesothelioma
NCT00025207 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00025207 |
|---|---|
| Title | Gefitinib in Treating Patients With Malignant Mesothelioma |
| Official title | A Phase II Study Of ZD 1839 (NSC 715055, IND 61187) In Patients With Malignant Mesothelioma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma |
| Intervention type | Drug, Other |
| Interventions | gefitinib, laboratory biomarker analysis |
| Enrollment | 40 |
| Start date | Sep 1, 2001 |
| Primary completion | Feb 1, 2006 |
| First posted | Sep 10, 2003 |
| Last update posted | Jan 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: